D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Investing.com - BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN), currently trading at $63.50 and rated "Great" by InvestingPro’s comprehensive health score system, received a reiterated Overweight rating and $90.00 price target from Cantor Fitzgerald on Tuesday. The stock appears undervalued according to InvestingPro’s Fair Value analysis.
The research firm noted that BioMarin topped expectations on both top and bottom lines, with positive performance across its product portfolio. The company’s impressive 19.36% revenue growth and industry-leading 81% gross margin demonstrate strong operational execution. The beats came from both the company’s enzyme replacement business and Voxzogo.
Cantor Fitzgerald highlighted that Naglazyme, Vimizim, and Aldurazyme were particularly strong performers among the company’s products during the reported period.
BioMarin has improved its financial outlook, with operating margins now expected to be 33-34% for the year, up from the previous guidance of 32-33%.
The firm also noted that BioMarin management plans to update its 2027 and long-term revenue guidance by the end of 2025, acknowledging the need to revise projections in light of competitive dynamics for Voxzogo.
In other recent news, BioMarin Pharmaceutical Inc. reported impressive financial results for the second quarter of 2025, significantly surpassing analyst expectations. The company’s earnings per share (EPS) reached $1.44, exceeding the forecasted $0.83, representing a 73.49% surprise. Revenue also outperformed estimates, coming in at $825 million, compared to the anticipated $760.37 million. This strong performance was attributed to a 20% year-over-year growth in Voxzogo and a 15% increase in enzyme revenues. Analysts at Stifel and TD Cowen reiterated their Buy ratings for BioMarin, with price targets set at $91.00 and $120.00, respectively. UBS also maintained a Buy rating, raising its price target slightly to $114.00, highlighting the company’s continued execution in its enzyme replacement therapy business. Bernstein SocGen Group echoed a similar sentiment, reiterating an Outperform rating with a $95.00 price target. These developments reflect BioMarin’s disciplined operational approach and potential for future growth as noted by analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.